

AMENDMENTS TO THE CLAIMS

1-49. (Canceled).

50. (Currently amended) A composition for affecting weight loss comprising ~~a weight loss affecting amount of a combination of:~~

(a) ~~naltrexone or a pharmaceutically acceptable salt thereof;~~ and

(~~b~~) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof in an amount effective to induce weight loss in an individual; and

(b) naltrexone or a pharmaceutically acceptable salt thereof in an amount effective to enhance the weight loss effect of the bupropion or salt thereof;

wherein said composition is formulated for oral administration in a single oral dosage form.

51. (Currently amended) The composition of claim 50, wherein said ~~combination~~ composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

52. (Currently amended) The composition of claim 50, wherein said ~~combination~~ composition comprises about 30 mg to about ~~300~~ 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

53. (Currently amended) The composition of claim 50, wherein said ~~combination~~ composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about ~~300~~ 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

54. (Withdrawn) The composition of claim 50, further comprising zonisamide or a pharmaceutically acceptable salt thereof.

55. (Currently amended) A pharmaceutical composition for affecting weight loss comprising ~~a weight loss affecting amount of a combination of:~~

(a) ~~naltrexone or a pharmaceutically acceptable salt thereof;~~ and

(~~b~~) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof in an amount effective to induce weight loss in an individual;

(b) naltrexone or a pharmaceutically acceptable salt thereof in an amount effective to enhance the weight-reducing effect of the bupropion or salt thereof; and

Application No.: 10/828,795
Filing Date.: April 21, 2004

a pharmaceutically acceptable excipient, diluent, or carrier, wherein said composition is formulated into a single oral dosage form~~for oral administration~~.

56. (Currently amended) The pharmaceutical composition of claim 55, wherein said ~~combination~~ composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

57. (Currently amended) The pharmaceutical composition of claim 55, wherein said ~~combination~~ composition comprises about 30 mg to about ~~300~~ 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

58. (Currently amended) The pharmaceutical composition of claim 55, wherein said ~~combination~~ com position comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about ~~300~~ 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

59. (Withdrawn) The composition of claim 55, further comprising zonisamide or a pharmaceutically acceptable salt thereof.

60-66. (Canceled).